Logo image of RAPP

RAPPORT THERAPEUTICS INC (RAPP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RAPP - US75383L1026 - Common Stock

27.41 USD
-1.14 (-3.99%)
Last: 12/2/2025, 2:33:04 PM
Fundamental Rating

3

RAPP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. RAPP has a great financial health rating, but its profitability evaluates not so good. RAPP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RAPP has reported negative net income.
RAPP had a negative operating cash flow in the past year.
RAPP Yearly Net Income VS EBIT VS OCF VS FCFRAPP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of RAPP (-18.25%) is better than 60.42% of its industry peers.
RAPP has a better Return On Equity (-19.10%) than 67.71% of its industry peers.
Industry RankSector Rank
ROA -18.25%
ROE -19.1%
ROIC N/A
ROA(3y)-26.98%
ROA(5y)N/A
ROE(3y)-34.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RAPP Yearly ROA, ROE, ROICRAPP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RAPP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPP Yearly Profit, Operating, Gross MarginsRAPP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for RAPP has been increased compared to 1 year ago.
RAPP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RAPP Yearly Shares OutstandingRAPP Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
RAPP Yearly Total Debt VS Total AssetsRAPP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 34.37 indicates that RAPP is not in any danger for bankruptcy at the moment.
The Altman-Z score of RAPP (34.37) is better than 93.75% of its industry peers.
RAPP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.37
ROIC/WACCN/A
WACCN/A
RAPP Yearly LT Debt VS Equity VS FCFRAPP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 36.37 indicates that RAPP has no problem at all paying its short term obligations.
RAPP has a better Current ratio (36.37) than 97.92% of its industry peers.
A Quick Ratio of 36.37 indicates that RAPP has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 36.37, RAPP belongs to the best of the industry, outperforming 97.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 36.37
Quick Ratio 36.37
RAPP Yearly Current Assets VS Current LiabilitesRAPP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for RAPP have decreased by -3.35% in the last year.
EPS 1Y (TTM)-3.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RAPP will show a small growth in Earnings Per Share. The EPS will grow by 0.22% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.34%
EPS Next 2Y-2.91%
EPS Next 3Y-8.65%
EPS Next 5Y0.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPP Yearly Revenue VS EstimatesRAPP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 200M 400M 600M 800M
RAPP Yearly EPS VS EstimatesRAPP Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RAPP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RAPP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPP Price Earnings VS Forward Price EarningsRAPP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPP Per share dataRAPP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as RAPP's earnings are expected to decrease with -8.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.91%
EPS Next 3Y-8.65%

More info and screens

0

5. Dividend

5.1 Amount

RAPP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPPORT THERAPEUTICS INC

NASDAQ:RAPP (12/2/2025, 2:33:04 PM)

27.41

-1.14 (-3.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-09 2026-03-09
Inst Owners84%
Inst Owner Change33.32%
Ins Owners5.01%
Ins Owner Change-0.77%
Market Cap1.31B
Revenue(TTM)N/A
Net Income(TTM)-97.70M
Analysts84.29
Price Target53.19 (94.05%)
Short Float %4.45%
Short Ratio4.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.91%
Min EPS beat(2)10.23%
Max EPS beat(2)11.59%
EPS beat(4)4
Avg EPS beat(4)11.17%
Min EPS beat(4)10.23%
Max EPS beat(4)12.28%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.83%
PT rev (3m)52.46%
EPS NQ rev (1m)17.09%
EPS NQ rev (3m)22.5%
EPS NY rev (1m)0%
EPS NY rev (3m)3.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.55
P/tB 2.55
EV/EBITDA N/A
EPS(TTM)-2.71
EYN/A
EPS(NY)-4
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS0
BVpS10.73
TBVpS10.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.25%
ROE -19.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.98%
ROA(5y)N/A
ROE(3y)-34.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 36.37
Quick Ratio 36.37
Altman-Z 34.37
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1213.57%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42%
EPS Next Y18.34%
EPS Next 2Y-2.91%
EPS Next 3Y-8.65%
EPS Next 5Y0.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-52.27%
EBIT Next 3Y-45.73%
EBIT Next 5YN/A
FCF growth 1Y-133.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.5%
OCF growth 3YN/A
OCF growth 5YN/A

RAPPORT THERAPEUTICS INC / RAPP FAQ

What is the fundamental rating for RAPP stock?

ChartMill assigns a fundamental rating of 3 / 10 to RAPP.


What is the valuation status of RAPPORT THERAPEUTICS INC (RAPP) stock?

ChartMill assigns a valuation rating of 0 / 10 to RAPPORT THERAPEUTICS INC (RAPP). This can be considered as Overvalued.


What is the profitability of RAPP stock?

RAPPORT THERAPEUTICS INC (RAPP) has a profitability rating of 1 / 10.


What is the financial health of RAPPORT THERAPEUTICS INC (RAPP) stock?

The financial health rating of RAPPORT THERAPEUTICS INC (RAPP) is 8 / 10.


Can you provide the expected EPS growth for RAPP stock?

The Earnings per Share (EPS) of RAPPORT THERAPEUTICS INC (RAPP) is expected to grow by 18.34% in the next year.